

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.–27. (Canceled).

28. (Currently Amended) A method of treating a patient with having a neurodegenerative disease characterized by extracellular plaques, the method comprising administering to the patient a herpes simplex virus (HSV) amplicon particle produced by a helper virus-free method comprising transfecting a cell with: (a) an amplicon plasmid comprising an HSV origin of replication, an HSV cleavage/packaging signal, and a heterologous transgene ~~expressible in the host cell~~, (b) one or more vectors that, individually or collectively, encode all essential HSV genes but exclude all cleavage/packaging signals, and (c) a ~~vector~~ nucleic acid encoding an accessory protein[.]; wherein the heterologous transgene encodes a therapeutic protein that improves one or more symptoms of the neurodegenerative disease.

29. (Original) The method of claim 28, wherein the neurodegenerative disease is Alzheimer's disease.

30. (Currently Amended) The method of claim 28, wherein the heterologous transgene encodes a molecular adjuvant.

31. (Currently Amended) The method of claim ~~[[28]]~~ 30, wherein the molecular adjuvant is tetanus toxin Fragment C or keyhole limpet hemocyanin.

32. (Canceled).

33. (Currently Amended) The method of claim 28, wherein the heterologous transgene encodes A β .

34. (Currently Amended) The method of claim 28, wherein the heterologous transgene encodes both A β and a molecular adjuvant.

35–48. (Canceled).

49. (New) The method of claim 30, wherein the molecular adjuvant induces a Th2-mediated immune response.

50. (New) The method of claim 28, wherein the accessory protein comprises a virion host shut-off protein.